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DIETARY SUPPLEMENTS AND STRUCTURE-
FUNCTION CLAIMS: THE DYSFUNCTIONAL
STRUCTURE OF CURRENT REGULATION
Matthew W. Lindsey*
I. INTRODUCTION
Twenty percent of Americans report using one of the more
than thirty thousand dietary supplement products generated by an
estimated one thousand manufacturers, contributing to an industry
exceeding twenty billion dollars globally.' Fueled by increasing pub-
lic interest in individual health, dietary supplement manufacturers in
the United States (U.S.) continue to exploit the weaknesses in the
way the Food and Drug Administration (FDA) regulates these prod-
ucts. Dietary supplement manufacturers perpetuate the perceived
safety of supplements through the advertisement of structure-
function claims, which many consumers mistakenly assume to be the
same as FDA-regulated health claims.
Structure-function claims are a subset of health claims, and while
the FDA has yet to provide a precise definition, these claims may be
identified as any assertion that states, suggests, or implies the role of
a food category, a food, or one of its constituents in the growth, de-
* Matthew W. Lindsey is a May 2010 Juris Doctor candidate at the University
of Arkansas School of Law, Fayetteville, Arkansas. This comment received the
University of Arkansas Journal of Food Law &Policy's 2009 Annual Arent Fox/Dale
Bumpers Excellence in Writing Award. The author would like to thank Professor
Robert B. Leflar for his direction in the preparation of this comment. The author
would also like to thank his wife Blair for her unwavering encouragement and sup-
port.
1. Lars Noah & Barbara A. Noah, A Drug By Any Other Name..: Paradoxes in
Dietary Supplement Risk Regulation, 17 STAN. L. & POL'Y REv. 165, 165 (2006); see also
Katherine Wong, New Mandatory Reporting Requirements for Dietary Supplements and
Nonprescription Drugs Solve Very Little, 35J.L. MED. & ETHics 336, 336 (2007).
2. See discussion infta Part III.A.3-III.A.4.
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velopment, or normal physiological function of the body.! Stated
differently, a structure-function claim asserts that a specific food or
ingredient aids in the normal functioning of the body. Conversely, a
disease or risk reduction claim states, suggests, or implies that the
consumption of a specific food or ingredient significantly reduces
the development of a human disease.' For example, the claim "a diet
high in calcium may reduce the risk of osteoporosis" is a risk reduc-
tion claim, while the claim "a diet high in calcium aids in the growth
and maintenance of bones" is a structure-function claim.'
The average consumer's inability to distinguish between disease
and structure-function claims combined with a lack of premarket
approval for dietary supplements has allowed dangerous products
into the market leading to preventable deaths.' Unlike prescription
medications, dietary supplements are not subjected to premarket
scientific analysis or clinical trials before the FDA approves a prod-
uct for consumer use.! Instead, the FDA restricts or prohibits the
sale of a certain supplement only after the agency receives well-
documented reports of health risks associated with the product.'
3. See 21 U.S.C § 343(r)(6) (2000) (explaining, "a statement for a dietary sup-
plement may be made if...[it] describes the role of a nutrient or dietary ingredient
intended to affect the structure or function in humans"); see also 21 C.F.R. §
101.93(f) (2000) (restating the types of structure-function claims allowable under
§343(r)(6)). For a detailed source of information explaining the lack of a precise
definition for structure-function claims, see CENTER FOR FOOD SAFETY AND APPLIED
NUTRITION, U.S. FOOD AND DRUG ADMIN. (FDA), STRUCTURE/FUNCTION CLAIMS:
SMALL ENTITY COMPLIANCE GUIDE, (Jan. 2002), available at www.fda.gov/
ohrms/dockets/98fr/98n-0044.gdlOOO.pdf.
4. See 21 C.F.R. § 101.93 (g)(1) (2000) (defining disease as, "damage to an or-
gan, part, structure, or system of the body such that it does not function properly");
see also 21 C.F.R. §§ 101.93(g)(2)(i)-101.93(g)(2)(x) (2000) (listing ten criteria for
determining whether a statement is a disease claim). For an explanation of these
ten criterion, see CENTER FOR FOOD SAFETY AND APPLIED NUTRITION, supra note 3, at
4-11; see generally Nicole Coutrelis, The Legal Status and Regulatory Context of "Health
Foods" in the European Union, 58 FOOD & DRUG L.J. 35, 48 (2003).
5. Martijn B. Katan & Nicole M. de Roos, Toward Evidence-Based Health Claims
for Foods, 299 Sc. MAG., 206, 207 (2003), available at http://www.sciencemag.org/
cgi/reprint/299/5604/206.pdf.
6. See discussion infra Part III.
7. Peter Cohen, Science, Politics, and the Regulation of Dietary Supplements: It's
Time to Repeal DSHEA, 31 AM.J.L & MED. 175, 182 (2005).
8. See generally Dietary Supplement Health and Education Act of 1994
(DSHEA), Pub. L. No. 103-417, 108 Stat. 4325, [hereinafter DSHEA] (codified as
various amended sections of 21 U.S.C. §§ 301-399 (1994)). To date, ephedra is the
only supplement to have been banned by the FDA when the ingredient was de-
clared adulterated under the provisions of the DSHEA. See also Consumer Reports,
Dangerous Supplements: Still at Large, (May 2004) available at http://
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By contrast, manufacturers in the European Union (EU) are ex-
cluded from including health claims on their product labels.' How-
ever, policymakers in the EU are making progress as the scheduled
effective date for the EU Health Claims Directive approaches."o Due
to go into force January 1, 2010, the Health Claims Directive re-
quires the support of Member States to administer and enforce food
law regulations adopted by the European Parliament." Similar to
the FDA, the European Food Safety Authority (EFSA) seeks to en-
sure the safety of the food supply.'2  Any general similarities end
there. Unlike the FDA, the EFSA is an independent agency provid-
ing scientific advice and gathering data related to the potential risks
a dietary supplement may pose to humans before the product is avail-
able for purchase."
In 1994, the FDA began drawing attention to the risks associ-
ated with the consumption of ephedra in a series of consumer re-
ports and medical bulletins." Ten years and at least 155 ephedra-
related deaths later, the FDA finally banned the sale of dietary sup-
plements containing the ephedrine alkaloid on April 12, 2004.'" The
www.consumerreports.org/cro/food/diet-nutrition/dangerous-supplements/danger-
ous-supplements-504/overview/index.htm (quoting Bruce Silverglade, legal direc-
tor for the Center for Science in the Public Interest (CSPI), "[T]he standards for
demonstrating a supplement is hazardous are so high that it can take the FDA years
to build a case"); see also Reilley Michelle Dunne, How Much Regulation Can We Swal-
low? The Ban on Ephedra and How it May Affect Your Access to Dietary Supplements, 31
J. LEGIS. 351, 374 (2005); see also Henry Miller & David Longtin, Death by Dietary
Supplement: How to Regulate a Booming Industry, 102 POLICY REVIEW 15, 16 (2000).
9. Katan & de Roos, supra note 5, at 206 (explaining the traditional European
view that foods are either harmful or harmless, therefore, claims that dietary sup-
plements can treat or prevent disease are forbidden).
10. Regulation 1924/2006, 2006 O.J. (L 404) 9 (EC) [hereinafter Health Claims
Directive].
11. Steve Keane, Can a Consumer's Right to Know Survive the WTO?: The Case of
Food Labeling, 16 TRANSNAT'L & CONTEMP. PROBS. 291, 294 (2006).
12. Emilie H. Leibovitch, Food Safety Regulation in the European Union: Toward
Unavoidable Centralization of Regulatory Powers, 43 TEX. INT'L L.J. 429, 434 (2008).
13. Id.
14. See U.S. Food and Drug Administration (FDA), Adverse Events with Ephedra
and Other Botanical Dietary Supplements, FDA Medical Bulletin (Sept. 1994), available
at http://www.fda.gov/Food/DietarySupplements/ Alerts/ucm 1 1208.htm (noting
the FDA received an increasing number of reports of adverse reactions associated
with the use of products containing ephedra); See also Noah, supra note 1, at 182.
15. 21 C.F.R. § 119.1 (2004) (stating, "dietary supplements containing ephedrine
alkaloids are adulterated under section 402(f)(1)(A) of the Federal Food, Drug, and
Cosmetic Act); see also Carol Rados, Ephedra Ban: No Shortage of Reasons, FDA
CONSUMER MAGAZINE (March/April 2004) available at http://perma-
nent.access.gpo.gov/Lps1609/www.fda.gov/fdac/features/2004/203ephedra.htm
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causes for the delays were threefold: 1) the FDA's inability to link
undesirable effects with specific supplements; 2) the lack of premar-
ket approval for dietary supplements; and 3) the consumer percep-
tion that all dietary supplements safely increase desirable aspects of
proper bodily function.
Part II describes the regulatory and market conditions preced-
ing the Dietary Supplement Health and Education Act of 1994
(DSHEA) in the U.S. and the European Food Supplement Directive
of 2002 in the EU. Part III discusses the current risks that remain
despite attempts at regulation, as well as the potential for future
harm to consumers due to insufficient governmental involvement
and regulation within the dietary supplement industry. Part IV then
compares the various regulatory schemes implemented and pro-
posed in both markets designed to police the sale of dietary sup-
plements. Finally, Part V suggests that both premarket approval and
prohibition of structure-function claims are necessary to ensure the
public's safety. This Article provides a comparative analysis whereby
the strengths and weaknesses of both the U.S. and EU regulatory
schemes may be examined in order to improve the effectiveness of
regulation.
II. HISTORICAL BACKGROUND
Prior to the Dietary Supplement Health and Education Act of
1994 (DSHEA), the FDA regulated dietary supplements as food ad-
ditives under the Food, Drug and Cosmetics Act and required pre-
market approval before products entered the marketplace." Then,
in 1989, the FDA linked over 1,500 cases of permanent disability
and at least thirty-eight deaths to L-Tryptophan" supplements.
I (reflecting final rule to ban dietary supplements containing ephedra effective April
12, 2004); see also Mark Moran, Did Delay of Ephedra Ban Cause Unnecessary Deaths?,
39 PSYCHIATRIC NEWS 3, 24 (2004) available at http://pn.psychiatry
online.org/cgi/content/full/39/3/24.
16. Food, Drug and Cosmetics Act, 21 U.S.C. § 321(s) (1992).
17. L-Tryptophan is an essential amino acid, which can be used to treat insomnia
and anxiety when taken as a supplement. See generally Center for Food Safety and
Applied Nutrition, U.S. Food and Drug Administration (FDA), Economic Characteri-
zation of the Dietary Supplement Industry Final Report, at Table 4-3 (March 1999) avail-
able at http://www.rti.org/pubs/econ char.pdf.
18. Center for Food Safety and Applied Nutrition, U.S. Food and Drug Admini-
stration (FDA), Information Paper on L-tryptophan and 5-hydroxy-L-tryptophan (Feb.
2001) available at http://www.cfsan.fda.gov/~dms/ds-trypl.html; see also, Jennifer
Akre Hill, Comment, Creating Balance: Problems Within DSHEA and Suggestions for
Reform, 2 J. FOOD L. & POL'Y 361, 370 (2006).
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Fearing the dietary supplement industry was in danger, manufactur-
ers responded with a massive lobbying campaign designed to fight
greater FDA regulation." Part of this campaign included a series of
television advertisements depicting actor "Mel Gibson handcuffed
by FDA agents for possessing vitamins".' Backed by Senator Orin
Hatch of Utah, the home base of many supplement manufacturers,
the DSHEA was passed over the objections of the FDA." The
DSHEA established dietary supplements as a new class of food
product not subject to the regulations applied to food additives or
drugs." In essence, the DSHEA took away the authority of the FDA
to regulate dietary substances before they entered the marketplace,
and replaced it with a system in which the FDA is limited to retroac-
tively removing products after the harm has already occurred. The
result: Congress substantially reduced governmental oversight of
dietary supplements when it decided consumers are capable of mak-
ing informed decisions regarding the supplements they may choose
to take." Then, Congress passed the Dietary Supplement and Non-
prescription Drug Consumer Protection Act of 2007 (DSNDCPA of
2007) in an effort to address the shortcomings of the DSHEA.2' The
DSNDCPA of 2007 attempts to limit the shortcomings of the
DSHEA by requiring manufacturers to report instances of undesir-
able effects associated with the use of dietary supplements.
19. Henry Miller & David Longtin, Death by Dietary Supplement: How to Regulate a
Booming Industry, 102 POLICY REVIEW 15, 16 (2000).
20. Id.
21. Id.; See generally Loren Israelsen & Thomas Aarts, DSHEA Ten Years Later:
Now What?, NUTRTION BUS. J., June 2004, available at http://
www.supplementquality.com/editorials/DSHEA-anniversary.html (explaining the
DSHEA was a "political Hail Mary" and that "last-minute deal making resulted in
the addition of the structure-function claim disclaimer").
22. See S. Rep. No. 103-410, at 2 (1994) (explaining the purpose of DSHEA is
"to clarify that dietary supplements are not drugs or food additives, that dietary
supplements should not be regulated as drugs, and that burden of proof is on the
Food and Drug Administration (FDA) to prove that a product is unsafe before it
can be removed from the marketplace"); see also Miller & Longtin, supra note 19, at
16.
23. Wong, supra note 1, at 336-37.
24. Dietary Supplement and Nonprescription Drug Consumer Protection Act,
Pub. L. No. 109-462 (2007) (codified as amended section of 21 U.S.C. § 371 (2007))
[hereinafter DSNDCPA of 2007]. Although the Dietary Supplement and Nonpre-
scription Drug Consumer Protection Act of 2007 is commonly referred to as
DSNDCPA, this Article uses DSNDCPA of 2007 to help distinguish it from the
DSHEA.
25. See infra Part IV.
205
JOURNAL OF FOOD LAW & POLICY
By contrast, the traditional EU approach strictly limits the avail-
ability and advertising of dietary supplements. Passed in 2002, the
EU Food Supplement Directive, Directive 2002/46/EC (Food Sup-
plement Directive), proclaims the need to protect consumers from
unsafe products that mislead, and to prevent presenting food as
medicine.2 ' However, during this same period, many European gov-
ernments began promoting the use of certain dietary supplements."
For instance, it is illegal for manufacturers to state that a supple-
ment high in folic acid reduces the risk of birth defects," yet many
European governments advocate that would-be mothers take these
supplements.'
In response to the multiplicity of rules and policies among the
EU Member States and the prohibition of certain claims supported
by significant scientific authority," the European Food Safety Author-
ity (EFSA) pushed Regulation 1924/2006 (Health Claims Directive)
through the European Council (EC) in December 2006." The Health
Claims Directive seeks to create a framework for standardizing and
eventually permitting health and structure-function claims on food
labels.' The EFSA's charge is to implement nutrient profiles and
criteria by January 1, 2010 in order to govern proposed claims."
26. Council Directive 2002/46, 2002 O.J. (L 183) 51 (EC) [hereinafter Food
Supplement Directive].
27. See e.g., Richard A. Hubner, et al., Should Folic Acid Fortification be Mandatory?
No, 334 BRITISH MED. J. 1253 (2007), available at http://www.
bmj.com/cgi/reprint/334/7606/1253 (explaining "the UK's Food Standards
Agency recently proposed mandatory folic acid fortification of some foods"); see
also Bruce Jancin, Added Folic Acid Lowers Congenital Heart Defects Risk: Preconceptual
Supplementation Backed, 43 OB.GYN. NEWS 24 (2008) (noting the recent media cam-
paign by the Dutch government to encourage women take folic acid before concep-
tion).
28. See Council Directive 2000/13, art. 2, §1b, 2000 O.J. (L 109) 29 (EC) (Stat-
ing labeling must not attribute to any food ..the property of preventing, treating or
curing a human disease, or refer to such properties").
29. Katan, & de Roos, supra note 5, at 206.
30. For instance, it is well recognized that folic acid supplements prevent birth
defects for mothers who do not receive enough of the vitamin through their regular
diet. See Centers for Disease Control and Prevention, Dept. of Health and Human
Services, Facts about Folic Acid, http://www.cdc.gov/ncbddd/folicacid/basics.htm
(last visited Oct. 31, 2009).
31. Commission Regulation 1924/2006, 2006 O.J. (L 404) 9 (EC) [hereinafter
Health Claims Directive].
32. Christian Falk, United States: The New EU Health Claims Regulation: Tightened
Rules for Advertising and Labeling of Foodstuffs, Faegre & Benson LLP (Sep. 8, 2008),
http://www.mondaq.com/article.asp?articleid=65996 (last visited Oct. 31, 2009).
33. Jon Felce, European Union Food Labeling and Packaging: The Need to Strike a
Balance, 63 FOOD & DRUG L.J. 113, 115 (2008).
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III. THE DANGER OF CONSUMERS' INACCURATE PERCEPTION OF
DIETARY SUPPLEMENT LABELING AND HEALTH CLAIMS
Nevertheless, new requirements and regulations covering in-
gredients with the potential for use in dietary supplements might
not be enough to protect consumers from their inaccurate beliefs
regarding structure-function claims and government involvement in
the dietary supplement industry. Research shows that many con-
sumers misunderstand the role of government in regulating sup-
plements, do not understand the required disclaimers on labels that
contain structure-function claims, do not discuss supplement use
with their medical providers, and often concurrently take supple-
ments and prescription medications without realizing the very real
possibility of dangerous interactions.'
A. Consumer Misperception
Dietary supplements, like drugs, have risks and side effects, but
are generally self-prescribed." This is especially worrisome consider-
ing the amount of inaccurate information about the safe use and
potential risks of supplements. Adverse reactions to supplement use
resulted in 26,000 calls to U.S. poison control centers in 2007, with
at least one death attributable to supplement exposure."
1. Megadosing
One common misperception is that because dietary supple-
ments are sold over the counter (OTC), some with no direction on
the label, they are safe to take even in high doses." This is com-
monly known as megadosing," and many people continue to take
large doses of various supplements such as vitamin C." Although
34. See infra Part III.A.1-III.B
35. American Cancer Society, Dietary Supplements: How to Know What is Safe,
http://www.cancer.org/docroot/ETO/content/ETO_5_3xHow-toKnowWhat_
Is Safe Choosing-andUsing-DietarySupplements.asp (last visited Oct. 31, 2009).
36. Id.
37. Id.
38. For an overview of megadosing, sometimes referred to as "megavitamin
therapy", see generally BC Cancer Agency, Vitamin Therapy, Megadose/ Orthomolecular
Therapy, http://www.bccancer.bc.ca/PPI/Unconventional Therapies/Vitamin
TherapyMegadoseOrthomolecularTherapy.htm (last visited Oct. 31, 2009).
39. Douglas RM, et al., Vitamin C for Preventing and Treating the Common Cold
2007 COCHRANE DATABASE OF SYSTEMATIC REVIEWS 3, available at
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there has never been any scientific evidence to show large doses of
vitamin C can prevent or cure the common cold, many people still
believe this is true.o In fact, megadosing certain vitamins and min-
erals has actually been shown to cause dangerous side effects." Too
much vitamin C can interfere with the body's ability to absorb cop-
per, a metal essential to the body's proper functioning." Too much
phosphorous can inhibit the absorption of calcium, a mineral vital
to the maintenance of healthy bones, while high doses of vitamins A,
D, and K are not easily digested by the body and can quickly reach
toxic levels."
2. All Natural
Another common mistaken belief is that supplements marketed
as "all natural" are safe to take in any amount." This is simply not
true. Just because something is natural does not mean that it is
good for you. Different parts of plants contain many different
chemicals, which can have very different effects on humans." The
popular supplement ginkgo biloba, named after the tree from which
it is derived, is usually consumed as an extract prepared from the
dried leaves." However, people do not generally consume the tree's
fruit, and research links ingestion of the seed to fatal human poison-
ing." Additionally, ginkgo biloba extract (GBE) is a highly concen-
trated substance that appears to be more effective in treating health
ailments." While not considered all natural because of the altera-
tion from its natural state, GBE is generally preferred over ingesting
http://medschool.umaryland.edu/integrative/cochrane-reviews/cochrane-rev-
commoncold.asp.
40. American Cancer Society, supra note 35.
41. See Miranda Hitti, FDA Flags Megadose of Selenium Supplement, WEBMD
HEALTH NEWS (Apr. 9, 2008), http://www.webmd.com/news/20080409/fda-flags-
supplement-selenium-mega-dose (last visited Nov. 3, 2009) (noting selenium may
boost the immune system, but too much can lead to hair loss, muscle cramps,
fatigue, and skin blisters).
42. American Cancer Society, supra note 35.
43. Id.
44. Cohen, supra note 7, at 196 (indicating it is not uncommon for dietary sup-
plements claiming to be "all natural" contaminated with synthetic materials).
45. American Cancer Society, supra note 35.
46. University of Maryland Medical Center, Complementary Medicine: Echinacea,
http://www.umm.edu/altmed/ articles/ginkgo-biloba-000247.htm (last visited Nov.
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the leaves themselves. Therefore, all natural supplements are often
not as effective or helpful because they have not been refined to
remove dangerous chemicals or parts of a plant that do not contrib-
ute to the desired effects."
There can also be allergic reactions to substances that are all
natural. Some consumers take bee pollen to prevent hay fever, in-
crease energy, and to aid in memory.' The problem is some people
have serious allergies to various pollens without knowing it."
Documented reports have linked fatal reactions to the consumption
of bee pollen." With no scientific evidence supporting the idea that
bee pollen has benefits, combined with the risk of death, it is hard
to understand why some consumers buy the product."
People also tend to think that supplements such as echinacea'
and ginkgo biloba," ingested for their medicinal effects for thou-
sands of years, must be safe due to their continued use and popular-
ity." The truth is that while occasional use of these substances may
provide relief for certain conditions, it has not been until recently
that the medical profession has looked at the long-term effects of
daily use in higher doses." Without additional research, the side
effects of long-term supplement use remain uncertain.
3. Governmental Regulation
One of the most disturbing instances of consumer mispercep-
tion is the belief the FDA approves dietary supplements. In a recent
survey, ten percent of respondents indicated they believed dietary
supplements required FDA approval, while forty-two percent were
49. American Cancer Society, supra note 35.
50. See William Jarvis, Bee Pollen, NATIONAL COUNCIL AGAINST HEALTH FRAUD





54. Echinacea supplements are commonly ingested for their ability to promote a
healthy immune system, relieve pain, reduce inflammation, as well as its effects as
an antioxidant. See Ginkgo biloba, supra note 46.
55. See id. Ginkgo biloba is primarily used to increase blood flow to the brain,
with evidence suggesting it improves memory and learning among Alzheimer's
patients. See University of Maryland Medical Center, supra note 46.
56. American Cancer Society, supra note 35.
57. Id.
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unsure whether a product required approval or not." However, as
recently as 2001 another study found thirty-five percent of respon-
dents believed the FDA approved dietary supplements." Although
the data from the more recent survey may seem to indicate confu-
sion among consumers regarding governmental regulation is de-
creasing, it is worth noting that studies on the issue are scarce and
differing methodologies between experiments might explain the
disparity between these two results. Indeed, it is troubling any con-
sumers believe dietary supplements are FDA-approved.
The 2001 study also found that an individual's education had a
direct impact on his or her belief that the government approved
supplements.' Individuals whose highest level of education was
high school were over two-times more likely to be mistaken when
compared with those possessing a college education." This misun-
derstanding may provide a false sense of security regarding the
safety of dietary supplements. When people assume a product is
safe it only increases the likelihood injury will occur.
4. Labeling Confusion and Ineffectiveness
The DSHEA requires all products with structure-function claims
contain the disclaimer, "This statement has not been evaluated by
the Food and Drug Administration. This product is not intended to
diagnose, treat, cure, or prevent any disease." 2 In 2005, researchers
conducted the first published experiments to determine how con-
sumers interpret the different labels found on food and supplement
products." The analysis hypothesizes that once a consumer has de-
veloped a belief, new information is interpreted in a manner that
will confirm the preexisting belief.' For example, a purchaser may
hold the belief government watches out for consumers, and would
58. Bimal H. Ashar, et al., Patient's Understanding of the Regulation of Dietary Sup-
plements, 33 JOURNAL OF COMMUNITY HEALTH 22, 25 (2008) available at
http://www.medscape.com/viewarticle/570150_4.
59. Id. at 27.
60. Id. at 25.
61. Id. at 26.
62. 21 C.F.R. § 101.93(c) (2000).
63. Karen France & Paula Bone, Policy Makers' Paradigms and Evidence from Con-
sumer Interpretations of Dietary Supplement Labels, 39 J. OF CONSUMER AFF. 27, 34
(2005).
64. Id. The hypothesis relies on confirmatory bias theory, which predicts new
information is interpreted in a way to avoid information and explanations contra-
dictory to prior beliefs.
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not allow dangerous products to enter the marketplace.' This trust
in government may lead the purchaser to discount any disclaimer
found on a product's label.'
Another instance was recorded when a particular supplement,
such as the popular cold remedy Airborne," received publicity over
its ability to prevent a particular disease.' Under these circum-
stances, consumers were more likely to believe in the product's abil-
ity to prevent or treat a disease regardless of the DSHEA dis-
claimer." This indicates that where publicity and the FDA dis-
claimer come into contradiction people give more credibility to
positive press over a government warning. Also interesting is the
fact that people who place higher importance on disease prevention
and healthy living attributed more significance to structure-function
and disease claims." Additionally, the studies found heavy supple-
ment users are more likely to believe the FDA evaluates dietary sup-
plements despite the fact they are the ones most exposed to the
DSHEA disclaimer." The evidence collected during the study led
researchers to conclude consumers made no distinction between
non-regulated structure-function claims and FDA-approved disease
claims." This leads to the conclusion Congress was incorrect in
finding consumers were capable of making informed decisions re-
garding the dietary supplements they choose to take. The data sug-
gests people do not pay attention to the FDA disclaimer, and there-
fore need protection from themselves and their mistaken beliefs.
B. Failure to Disclose Supplement Use to Physicians
The fact consumers are uncertain as to the meaning of heath
and structure-function claims, as well as the misunderstanding and
65. Id. at 35.
66. Id. at 36.
67. Infra note 69.
68. France & Bone, supra note 63, at 36.
69. Id. As an example, the initial buzz surrounding Airborne, a supplement
which touted its ability to prevent and cure the common cold, caused consumers to
purchase the product en masse. Although the product bore the required FDA
disclaimer, the public perception was that the product was effective until significant
scientific research concluded Airborne's ability to prevent or cure the common cold
was unsubstantiated. Eventually, a class action lawsuit was initiated by those who
were misled. See Airborne Settlement, Settlement Information and Claim Filing Web-
site, http://www.airbornehealthsettlement.com (last visited Feb. 18, 2010).
70. France & Bone, supra note 63, at 34.
71. Id. at 47.
72. Id. at 46.
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ineffectiveness of disclaimers is exacerbated by the fact that people
who use supplements generally do not share this information with
their health care providers." Surveys indicate that as many as forty-
nine percent of Americans aged fifty-seven through eighty-five years
of age reported taking a dietary supplement in the preceding twelve
months." While most reported using a multivitamin, these seem-
ingly safe substances are not without their risks. Of the four percent
who believed they suffered an adverse reaction due to supplement
usage, over thirteen percent attributed it to multivitamins or mul-
timinerals." Moreover, studies indicate those who use prescription
drugs were more likely to be taking dietary supplements concur-
rently."
Evidence suggests consumers of dietary supplements are less
likely to reveal supplement usage when compared to prescription or
OTC medication." This is problematic because generally there are
no tests conducted on dietary supplements to determine potential
adverse interactions with prescription medication that can cause
dangerous reactions or death." Many medical professionals are also
unaware of the potential risks involved from mixing dietary supple-
ments and prescription drugs." This creates a dangerous situation
where the true effects of supplements go unreported.
A recent study revealed fifty-two percent of people in the U.S.
between the ages of fifty-seven and eighty-five concurrently took
prescription medications and dietary supplements." The article
notes the lack of current information regarding the simultaneous
use of drugs and supplements is sparse, which may contribute to the
adverse reactions." The study concludes by finding four percent of
the individuals who participated in the survey were at risk of having
a major adverse interaction.'
73. J.L. Greger, Dietary Supplement Use: Consumer Characteristics and Interests, 131
J. OF NUTRITION 1339S, 1342S (2001).
74. Babgaleh Timbo et al., Dietary Supplements in a National Survey: Prevalence of
Use and Reports of Adverse Events, 106 J. AM. DIETETIC Ass'N 12, 1966 (2006).
75. Id. at 1966.
76. Id. at 1972.
77. Id.
78. Cohen, supra note 7, at 195-96.
79. Noah, supra note 1, at 193.
80. Timbo, supra note 74, at 1972.
81. Id.
82. Id. at 1966.
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The fact many doctors do not ask their patients whether they
are currently taking a dietary supplement exacerbates the problem."
One reason many doctors do not ask patients about supplement use
is that they do not believe in the effectiveness of alternative medi-
cines.' Another reason commonly cited by physicians is that they
do not know enough about dietary supplements to give an informed
opinion to a patient who does inform them of supplement usage."
However, as the instances of adverse supplement-drug interactions
continue to increase, more sources are becoming available for doc-
tors to consult before a recommendation is given to the patient.'
When patients do not inform their doctor of their supplement
usage, the doctor is not receiving the information he or she needs to
make an accurate diagnosis. Supplement use has even been shown
to increase the symptoms and severity of diseases when combined
with prescription drugs." Thus, failure to report supplement use
and adverse events has led to inaccurate figures that under-represent
the harm done by dietary supplements." Moreover, this lack of re-
porting perpetuates a cycle that denies medical professionals and
nutritionists the information necessary to understand potential
harmful drug-supplement interactions.
C. Industry Practice
The risk of concurrent use of dietary supplements and prescrip-
tion drugs continues to increase as supplements enter into new ar-
eas of the food supply. As early as 1998, major corporations began
attempting to enter the supplement market in an effort to avoid the
83. Stacey Butterfield, If Physicians Don't Ask, Patients Won't Tell About CAM, ACP





87. For example, certain dietary supplements are known to increase the risk of
internal bleeding when taken with prescription blood thinners. See Nutrition
Counseling Services, Dietary Supplements, http://nutritionsowa.com/dietarysupple-
ments.aspx (last visited Feb. 18, 2010).
88. Keane, supra note 11, at 295.
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greater FDA regulation associated with functional foods." Func-
tional foods are products fortified with minerals, vitamins, or dietary
supplements and require that any ingredient provide taste, aroma,
nutritional value, or have a technological effect on the food such as
preservation, color, etc."
Campbell Soup Company marketed its popular V8 Juice with
the structure-function claim that the antioxidants contained in the
product help slow normal aging." Not only would this statement fail
to qualify as an FDA-approved health claim concerning the con-
sumption of fruits and vegetables due to its high levels of sodium,
the label is especially misleading because diets high in sodium have
been linked to high blood pressure, which is associated with aging.'
Campbell Soup is not alone. Another company marketed a line
of soup known as "Kitchen Prescription," which includes chicken
and noodle with Echinacea and split pea with St. John's Wort." Yet
another example is a caffeinated gum branded "Stay Alert,"" which
is being marketed as a dietary supplement. Caffeine is only ap-
proved for food use in non-alcoholic carbonated beverages, but be-
cause dietary supplements are not regulated as foods, manufacturers
seem to have found a loophole with this product containing the
name of a conventional food (gum) and sold alongside other chew-
ing gums."
By labeling a product as a supplement, the manufacturer is able
to avoid Generally Recognized As Safe requirements that these sub-
stances are not dangerous when used as food ingredients." More-
over, the addition of dietary supplements into food categories peo-
ple generally believe to be safe could increase the perception that
the supplements themselves are safe. Furthermore, as consumers
find dietary supplements introduced into new and different mar-
kets, the risk for adverse events and drug interactions may increase
as more people encounter these products.
89. Center for Science in the Public Interest, United States - A Good System Gone
Bad: Marketplace Implications and Consumer Impact, http://www.cspinet.org/





94. See Stay Alert Gum, http://www.stayalertgum.com (last visited March 9,
2009).
95. Center for Science in the Public Interest, supra note 89.
96. Id.
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IV. CURRENT REGULATORY SCHEMES IN THE U.S. AND Eu
The FDA's delay in banning ephedra caused a few states within
the U.S. to pass their own laws banning the sale of the supplement."
In the years following the FDA's own ban of ephedra, it became clear
the current voluntary reporting system for companies with informa-
tion regarding undesirable effects of supplement use was unwork-
able." Congress responded with the Dietary Supplement and Non-
prescription Drug Consumer Protection Act of 2007 (DSNDCPA of
2007)." The DSNDCPA of 2007 requires the mandatory filing of
Adverse Event Reports (AER) by manufacturers within fifteen days of
receiving such information from consumers.'" In order to facilitate
reporting, manufacturers are required to include contact informa-
tion on the labels of the supplements they produce.'o' Six months
after the implementation of mandatory AER reporting, the FDA an-
nounced over six hundred adverse events with at least five deaths
attributable to the ingestion of dietary supplements."
A. Weaknesses of Current U.S. Regulation
Most experts contend that even the new mandatory reporting
guidelines promulgated by the DSNDCPA of 2007 do not produce
figures that accurately represent the true number of adverse events
97. See 720 ILL. COMP. STAT. ANN. 602/1 (Supp. 1 2009); See, e.g., Jim Ritter,
Ephedra Sales Banned in Illinois: Linked to Strokes, Herbal Stimulant is Sold in Other
States, CHICAGO SUN-TIMES, (May 26, 2003) available at
http://www.encyclopedia.com/doc/ IP2-1485246.html (explaining Illinois became
the first state to ban ephedra); see also N.Y. GENERAL BUSINESS LAw § 391-0 (Supp. 1
2009); see, e.g., Chuck Bell, Consumers Union Applauds New York State Law Banning
Ephedra, CONSUMER UNION, Aug. 25, 2003, available at http://www.
consumersunion.org/pub/core-product-safety/000285.html (applauding New York
as the second state to ban the sale of ephedra); see also CAL. HEALTH AND SAFETY
CODE § 110423.100 (2004); see e.g. Jennifer Morey, Statewide Ephedra Ban Now in
Effect, THE TIMES-STANDARD, Jan. 4, 2004 (explaining the California law which took
effect two months before the FDA ban became effective).
98. Hill, supra note 18, at 380 (indicating the Inspector General for the Depart-
ment of Health and Human Services believed the voluntary system revealed less
than one percent all negative reactions to dietary supplement use).
99. DSMDCPA of 2007, supra note 24.
100. 21 U.S.C. § 379aa-1(c)(1) (2006).
101. 21 C.F.R. § 101.93(a) (2000).
102. ORTHOMOLECULAR MEDICINE NEWS SERVICE, FDA Claims "Food Supplement"
Deaths; Hides Details from Public, Oct. 9, 2008, available at http://www.
orthomolecular.org/resources/omns/v04nl3.shtml.
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linked to the consumption of dietary supplements.'" This is due, in
part, to the FDA's history of minimal monitoring of dietary supple-
ments post-DSHEA." As of 2004, the FDA's supplement division
consisted of sixty staff members working under a $10 million dollar
budget in an attempt to regulate an industry with revenues exceed-
ing $19 billion dollars annually.' In comparison, the FDA employs
forty-eight times as many people and spends forty-three times the
amount of money to regulate the drug industry, which sees revenues
only twelve times greater than the dietary supplement industry.'"
Prior to the passage of the DSNDCPA of 2007, all FDA data on
adverse events was solely the product of voluntary reporting submit-
ted by the manufacturers of the supplements themselves.' 7  Two
scholars analogize this to the IRS relying on taxpayers to provide
information on their own underreporting of income.' In fact, re-
cent court documents show makers of the best-selling brand of
ephedra supplement Metabolife'" received more than 13,000 cus-
tomer complaints regarding the product with none of these reports
ever disclosed to the FDA."o With such a lengthy history of under-
reported adverse events, it will take time for mandatory reporting to
create a difference in the regulation of supplements."'
What is surprising is that the FDA has refused to disclose the
information it receives regarding adverse events to the public or the
103. Wong, supra note 1, at 337.
104. See generally id.; see also Barbara A. Noah, A Review of the New York State Task
Force on Life & the Law's Report Dietary Supplements: Balancing Consumer Choice &
Safety, 33J.L. MED. & ETHICS 860, 862 (2005) (indicating that before mandatory re-
porting the FDA received reports of less than one percent of all adverse events
associated with dietary supplements).
105. Consumer Rep., Dangerous Supplements: Still at Large, (May 2004) available at
http-//www.consumerreports.org/cro/food/diet-nutrition/dangerous-supplements/
dangerous-supplements-504/overview/index.htm.
106. Id. (quoting William Hubbard, FDA associate commissioner for policy and
planning as saying, "The law has never been fully funded...[t]here's never been the
resources to do all the things the law would command us to do").
107. Hill, supra note 18, at 380.
108. Miller & Longtin, supra note 19, at 17.
109. ISI Brands, Metabolife, http://www.metabolife.com/ (last visited Nov. 23,
2009).
110. Associated Press, Criminal Investigation Sought for Diet Supplement Seller,
U.S.A. TODAY Aug. 15, 2002, available at http://www.usatoday.com/news/
health/2002-08-15-ephedra-x.htm (indicating supplement manufacturer denied
FDA requests for access to reports of adverse reactions over a period of several
years until the Justice Department became involve in a criminal investigation).
111. Wong, supra note 1, at 337.
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medical profession."' Now that the FDA is actively soliciting reports
of adverse events, one would assume this information would be
available to consumers so they may educate themselves and make
informed decisions, consistent with the spirit of the DSHEA."'
However, this is not the case, and the FDA has refused to release the
details of which specific supplements are causing problems."' With-
out full accountability for AERs, it seems the DSNDCPA of 2007 will
change little in the way the FDA regulates dietary supplements. Af-
ter all, even if the system works as intended, it will only serve to no-
tify the FDA when a particular product causes harm to consumers
rather than giving the FDA the ability to prevent these substances
from entering the market and injuring consumers in the first place.
B. The EU Approach
It is possible to view the EU approach of using a "positive list"
as existing on the opposite end of the spectrum when it comes to
regulation of dietary supplements. Between 1980 and 2000, Ger-
many tested more than 300 herbal remedies, finding approximately
two-thirds to be safe and at least minimally effective."' However,
even those substances approved for consumer use are regulated in
the same way as prescription drugs."' Consumer desire for greater
access to alternative medicines and herbal remedies, as well as pres-
sure from European supplement manufacturers, led to the creation
of the EFSA and the passage of the Health Claims Directive set to
take effect in 2009."' The Health Claims Directive focuses on the
ingredients used in manufacturing vitamins and minerals, maximum
112. ORTHOMOLECULAR MEDICINE NEWS SERVICE, supra note 102.
113. Id. While the FDA does release information identifying specific products the
agency has determined present a health risk, it does not release the details of the
Adverse Event Reports themselves. This appears to be in conflict with the Freedom
of Information Act (5 U.S.C. § 552 (2000)), but that issue is beyond the scope of
this Article.
114. ORTHOMOLECULAR MEDICINE NEWS SERVICE, supra note 102.
115. Miller & Longtin, supra note 19, at 16. Similar tests have been conducted in
various countries across the EU including Ireland, see M.M. O'Brien, et al., The
North/South Ireland Food Consumption Survey, 4 PUBLIC HEALTH NUTRITION 5b, 1069
(2001), and the United Kingdom, see Angela E. Johnson, et al., Dietary Supplement
Use Later in Life, 102 BRrTSH FOODJOURNAL 40 (2000).
116. Miller & Longtin, supra note 19, at 16.
117. Health Claims Directive, supra note 31; See also Leibovitch, supra note 12, at
435 (explaining that food scares during the 1990s and a lack of consistency in regu-
lation between countries were also contributing factors to the creation of the
EFSA).
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allowable dosages, labeling, presentation, and advertising of food
supplements."' In order to standardize manufacturing and market-
ing of supplements amongst Member States, the EFSA created a
"positive list" to be used by the manufacturers of food supple-
ments."9 To date, the EFSA has approved 112 ingredients, adding
them to the growing positive list.'o As ingredients are added, the
EFSA implicitly grants approval to manufacturers currently produc-
ing supplements containing substances on the positive list that con-
tinued production after the Health Claims Directive is allowed.'12
However, those manufacturers who produce supplements that
contain ingredients not included on the positive list may find it dif-
ficult to get those substances added. Studies estimate the required
testing necessary to get an ingredient onto the positive list costs be-
tween $110,000 and $350,000 USD, and can take two to three
years.'22 This presents a substantial obstacle to companies that cur-
rently make supplements with ingredients not on the positive list,
and will probably be enough to force many to end production of
certain supplements.'2  The Health Claims Directive also involves
the creation of nutrient profiles with which supplements must com-
ply in order to make certain claims.2 This has the potential to price
out small and medium sized businesses from making any claims at
all, leaving the larger manufacturers with a considerable advantage
when it comes to innovation and development of new claims. 2 1
These negative aspects of the Health Claims Directive seem to
outweigh any potential benefits. However, manufacturers and dis-
tributors should profit from a more secure legal environment cre-
ated by close regulation of claims.2 1 More importantly, consumers
will benefit from the standardization of claims, labeling, ingredients,
and manufacturing processes of supplements.'2 ' Additionally, a vast
118. Fiona LeCong, Food Supplements Directive: An Attempt to Restore the Public
Confidence in Food Law, 29 LoY. L.A. INT'L & COMP. L. REV. 105, 108 (2007).
119. Id.
120. Id.
121. These "positive lists" are found in Annexes I and II of the Food Supplements
Directive; see also LeCong, supra note 118, at 108.
122. Lecong, supra note 118, at 109.
123. Id.
124. Felce, supra note 33, at 115.
125. Id. at 116.
126. Leibovitch, supra note 12, at 436.
127. Keane, supra note 11, at 295.
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majority of nutrient claims will likely be unaffected as they already
meet the proposed requirements of the Health Claims Directive."1 2
V. THE NEED TO BAN STRUCTURE-FUNCTION CLAIMS AND REQUIRE
PREMARKET APPROVAL FOR SUPPLEMENTS
Taken together, the facts overwhelmingly indicate the need to
ban structure-function claims in the U.S. and prevent their future
use in the EU relating to all food products and dietary supplements.
The fact that the average consumer cannot distinguish a structure-
function claim from a disease claim alone should be enough to war-
rant their prohibition. If a specific claim has scientific support, it
should qualify as an approved health claim. It is simply too confus-
ing to have a system with two different types of claims, both making
very similar assertions, but where one is almost completely unregu-
lated. Either a substance prevents, treats, or cures a disease, or it
does not. If scientific evidence shows it does, manufacturers should
be permitted to make that claim on a product's label. If there is not
enough scientific evidence, manufacturers should not be allowed to
make any type of health claim. The evidence and research clearly
indicate disclaimers are not effective at conveying the intended mes-
sage to the consumer."
A. Recommendations for the U.S.
To effect change, President Obama will need to create proposals
that specifically seek to reform the regulation of dietary supplements
and overhaul the struggling FDA. Although Senators Hatch and
Harkin continue to defend the DSHEA," many members of Con-
gress have been vocal in their criticisms of the statute.' There is a
lot to be learned from the failures of the DSHEA including the pit-
falls of vague definitions and a lack of effective regulatory authority.
128. Felce, supra note 33, at 116.
129. See supra Part III.A.4.
130. See Loren Israelsen, What Obama Means for Functional Foods and Supplements:
Part I, Nutraingredients-USA, (Jan. 20, 2009), http://www.nutraingredients-
usa.com/On-your-radar/The-Obama-effect/What-Obama-means-for-functional-
foods-and-supplements-Part-1. (last visited Feb. 19, 2009).
131. Henry Waxman (D-Calif.) has been an outspoken critic of dietary supple-
ments. See Israelsen, supra note 130. Another DSHEA opponent is Senator Rich-
ard Durbin (D-Ill.), who happens to be one of the first key political figures to en-
dorse Obama. Id.
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Changes to the current structure of regulation should include a
return to a system of premarket approval for all dietary supple-
ments. The current regulatory scheme is obviously inefficient, with
the FDA resorting to advisory opinions and warnings instead of pre-
venting dangerous supplements from reaching the shelves." Addi-
tionally, the costs would not be as prohibitive as industry lobbyists
suggest. The FDA has already found many of the supplements cur-
rently sold safely promote good health and may help prevent dis-
ease.'" A system of premarket approval would also shift the costs of
supplement safety to the manufacturer.
Although the use of a positive list has its benefits, premarket
approval will provide consumers with the protection they need. This
is because there is little research on many of the ingredients found
in dietary supplements. To add a specific ingredient to a positive
list ignores the fact that some of these substances may cause dan-
gerous interactions when mixed with other ingredients already on a
positive list. Therefore, a system of premarket approval is best to
avoid this potentially fatal possibility.
The most efficient way to achieve these changes in the U.S. is by
repealing the DSHEA and replacing it with new legislation. In-
stead of trying to prove a specific supplement is unsafe, the FDA
should have the authority to require proof products are safe before
introduction to the public. This new legislation should provide an
exact definition of what constitutes a dietary supplement in order to
eliminate the uncertainty and the loopholes that currently exist.
B. Conclusion
These changes in the law will help to ensure that consumers of
dietary supplements are well informed, not misled, and have access
to products that are proven safe. This provides both legal security
132. The FDA has released reports of potential adverse effects associated with a
dietary supplement as recently as January 27, 2009. See U.S. Food and Drug Ad-
ministration (FDA), FDA Warns Consumers Against Dietary Supplement Containing
Undeclared Drug, FDA NEWS (2009), available at http://www.fda.gov/bbs/
topics/NEWS/2009/NEW01950.html (warning consumers about the risks of a
dietary supplement containing Sibutramine, a controlled substance with risks of
abuse and potentially dangerous health conditions).
133. See Center for Food Safety and Applied Nutrition, U.S. Food and Drug Ad-
ministration (FDA), Health Claims that Meet Significant Scientific Agreement
(SSA), http://www.cfsan.fda.gov/~dms/lab-ssa.html (last visited Feb. 18, 2009).
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and certainty to companies who choose to manufacture these sup-
plements. Proper regulation of the dietary supplement industry will
allow numerous benefits to consumers while decreasing the in-
stances of confusion and harm.

